Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
Company Directory
InSightec
5 Nachum Heth St., POB2059
Tirat Carmel
39120
Israel
[t] +972 52 8515097
[W] http://www.insightec.com
Collaborative agreement on exablate neuro technology
26 August, 2016
Insightec and Siemens have signed an agreement on the the development of integrated MRI and exablate neuro technology
ExAblate receives approval of Health Canada for uterine fibroids treatment
23 August, 2013
InSightec's ExAblate MR guided Focused Ultrasound therapy system receives approval of Health Canada for MRgFUS treatment of uterine fibroids and for pain palliation of bone metastases.
ExAblate receives extended CE Mark for benign and cancerous bone tumours
03 July, 2013
InSightec's ExAblate systems have received an extended European CE Mark for the local treatment of cancerous and benign primary and secondary bone tumours, including but not limited to multiple myeloma, bone metastases, osteoid osteoma as well as facet joint back pain.
InSightec's ExAblate Neuro to start pivotal Phase III trial for essential tremor treatment
20 February, 2013
InSightec receives FDA approval to begin the company's pivotal Phase III clinical trial for treatment of essential tremor using ExAblate Neuro.
InSightec completes additional financing of USD30.9m to develop focused ultrasound technology
10 December, 2012
InSightec completes the company's Series C financing totalling $30.9 million and includes an investment of $27.6 million by GE Healthcare and $3.3 million by other investors.
FDA approves new non-invasive, non-ionizing radiation therapy to treat pain from bone metastases
24 October, 2012
The US Food and Drug Administration (FDA) has approved InSightec's ExAblate MRI-guided focused ultrasound as a therapy to treat pain from bone metastases in patients who do not respond or cannot undergo radiation treatment for their pain.
US FDA allows InSightec to begin Phase I clinical trial for ExAblate Neuro system
22 August, 2012
InSightec receives approval from the US Food and Drug Administration (FDA) to begin a Phase I clinical trial evaluating the use of its ExAblate Neuro system for the treatment of patients with tremor dominant Parkinson's Disease.
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo